Navigation Links
ADVENTRX Announces Further Cost-Cutting Measures
Date:3/20/2009

SAN DIEGO, March 20 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that, effective April 3, it will reduce its full-time workforce to five employees and will discontinue substantially all of its development activities and fundamental business operations to provide additional time to consummate a strategic transaction or otherwise obtain financing. ADVENTRX's remaining employees, which will consist of its Chief Business Officer and Senior Vice President, its General Counsel, its Senior Vice President of Operations, its Vice President of Regulatory Affairs and Quality and its Manager of Accounting, will focus their efforts primarily on continuing to evaluate and execute strategic options.

"Along with the reductions we implemented in October 2008 and January 2009, and our prior cost-containment measures, the changes we announce today will extend our cash cliff and increase the opportunity for us to close a strategic transaction with one of the parties with whom we currently are in discussions or another company we identify in the future," said Brian M. Culley, ADVENTRX's Chief Business Officer.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company whose proprietary product candidates are designed to improve the safety and commercial potential of existing cancer treatments. In December 2008, the Company announced that it is exploring a range of strategic options, including the sale or disposition of one or more of its product candidate programs, a strategic business merger and other transactions that maximize the value of the Company's assets. More information can be found on ADVENTRX's web site at www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that the Company's recent cost-cutting measures, including those announced today, will negatively impact the Company's ability to consummate a strategic transaction; the risk that the Company will be unable to consummate a strategic or partnering transaction or raise sufficient capital and will be unable to continue as a going concern; the risk that the departure of the Company's former Chief Executive Officer and President, the Company's Executive Vice President and Chief Financial Officer and/or the Company's leadership by a committee of executive officers will negatively impact the Company's ability to consummate a strategic transaction or to maintain effective disclosure controls and procedures or internal control over financial reporting; the risk that the Company's stockholders will not approve a strategic or capital-raising transaction recommended by the Company's Board of Directors; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ADVENTRX Provides Update on Strategic Transaction Process
2. ADVENTRX Announces Further Cost-Cutting Measures
3. ADVENTRX Exploring Strategic Options
4. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
5. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
6. ADVENTRX Announces Restructuring and Cost Reduction Initiatives
7. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
8. ADVENTRX Settles Dispute With Former Licensee
9. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
10. ADVENTRX Appoints Vice President of Manufacturing
11. ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 2016 , ... Global Stem Cells Group, a ... Stem Cells Network (GSCN) and its affiliate Global Medical Training Network to ... and bone marrow therapies. , Through the new collaboration, Global Stem Cells ...
(Date:2/10/2016)... ... February 09, 2016 , ... Creation Technologies, leading global ... Highest Overall Customer Rating Award from Circuits Assembly , today announced its milestone ... USA, Canada, Mexico and China. , The EMS provider, known in the EMS ...
(Date:2/9/2016)... 9, 2016  Regenicin, Inc. (OTC Bulletin Board: ... the development and commercialization of regenerative cell therapies ... organs, recently reported the Company,s operating results for ... 2016. Lonza America , Inc. (the ... year in the process of consummating an agreement ...
(Date:2/9/2016)... ... February 08, 2016 , ... Net-Translators, ... today the launch of its revamped and improved website. In an on-going effort ... the redesigned website will better communicate how the company designs and delivers thorough, ...
Breaking Biology Technology:
(Date:2/5/2016)... 5, 2016 http://www.researchandmarkets.com/research/5kvw8m/global_facial ... "Global Facial Recognition Market 2016-2020" ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition of ... report to their offering. --> ... has announced the addition of the ...
(Date:2/3/2016)... DUBLIN , Feb. 3, 2016 /PRNewswire/ ... announced the addition of the "Emotion ... NLP, Machine Learning, and Others), Software Tools ... Application Areas, End Users,and Regions - Global ... offering. --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
Breaking Biology News(10 mins):